GlaxoSmithKline (NYSE:GSK)‘s stock had its “equal weight” rating reiterated by investment analysts at Barclays in a research report issued to clients and investors on Thursday.

Several other analysts have also commented on the stock. Zacks Investment Research upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a report on Tuesday, September 25th. Goldman Sachs Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research note on Wednesday, October 10th. Wolfe Research assumed coverage on shares of GlaxoSmithKline in a research note on Tuesday, October 23rd. They set a “market perform” rating for the company. ValuEngine raised shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a research note on Friday, October 19th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, September 25th. Thirteen research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus price target of $41.79.

Shares of GSK opened at $37.30 on Thursday. The company has a quick ratio of 0.63, a current ratio of 0.95 and a debt-to-equity ratio of 6.66. GlaxoSmithKline has a one year low of $34.83 and a one year high of $42.36. The stock has a market capitalization of $92.80 billion, a price-to-earnings ratio of 12.95, a P/E/G ratio of 2.51 and a beta of 0.81.

GlaxoSmithKline (NYSE:GSK) last issued its quarterly earnings data on Wednesday, October 31st. The pharmaceutical company reported $0.83 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.03). GlaxoSmithKline had a return on equity of 164.99% and a net margin of 5.78%. The company had revenue of $9.41 billion during the quarter, compared to analysts’ expectations of $10.55 billion. Sell-side analysts predict that GlaxoSmithKline will post 2.98 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. TD Asset Management Inc. boosted its stake in shares of GlaxoSmithKline by 1.7% during the 2nd quarter. TD Asset Management Inc. now owns 146,562 shares of the pharmaceutical company’s stock worth $5,908,000 after acquiring an additional 2,457 shares during the last quarter. CIBC Private Wealth Group LLC increased its holdings in GlaxoSmithKline by 23.5% in the 2nd quarter. CIBC Private Wealth Group LLC now owns 40,367 shares of the pharmaceutical company’s stock valued at $1,627,000 after acquiring an additional 7,691 shares during the last quarter. Dean Capital Investments Management LLC bought a new stake in GlaxoSmithKline in the 2nd quarter valued at $821,000. Bank of Hawaii increased its holdings in GlaxoSmithKline by 15.7% in the 2nd quarter. Bank of Hawaii now owns 44,200 shares of the pharmaceutical company’s stock valued at $1,782,000 after acquiring an additional 5,992 shares during the last quarter. Finally, Checchi Capital Advisers LLC increased its holdings in GlaxoSmithKline by 20.4% in the 2nd quarter. Checchi Capital Advisers LLC now owns 25,998 shares of the pharmaceutical company’s stock valued at $1,048,000 after acquiring an additional 4,402 shares during the last quarter. 10.97% of the stock is owned by institutional investors and hedge funds.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: Benefits of owning preferred stock

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.